SCHEMBL755094

SCHEMBL755094

CB(O)N1CCN(S(=O)(=O)c2ccc(C(C)=O)cc2)[C@H](C)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HTT P42858 1/20 0.49
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 3/20 0.43
POLB P06746 1/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPK1 P28482 2/20 0.42
HSD11B1 P28845 1/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734174 0.80 ALDH1A1 (0.54) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL752769 0.78 HSD11B1 (0.64) HSD11B1
SCHEMBL13489665 0.77 KMT2A (0.53) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL3609710 0.75 HSD11B1 (0.57) ALDH1A1HTTMAPTRAB9APOLB
SCHEMBL3609715 0.75 HSD11B1 (0.57) ALDH1A1HTTMAPTRAB9APOLB
SCHEMBL763824 0.74 MMP1 (0.56) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL14400848 0.74 MMP1 (0.56) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL13949678 0.73 ALDH1A1 (0.52) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL3602367 0.72 HSD11B1 (0.55) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL3602365 0.72 HSD11B1 (0.55) ALDH1A1HTTMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES GPR119, GLP1R, INSR ALDH1A1 655/4885HTT 954/4885MAPT 4610/4885
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses GPR119, GLP1R, INSR ALDH1A1 655/4885HTT 954/4885MAPT 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.